Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hua MedicineHUMDF 44 EV-to-EBIT is 1.24 as of Jul. 30, 2026. GuruFocus rates HUMDF with a GF Score™ of 44/100 and a GF Value™ of $1.17 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 692 Drug Manufacturers companies, Hua Medicine ranks better than 95.52% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hua Medicine's Enterprise Value for the quarter that ended in Dec. 2025 was $297.02 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $155.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine EV-to-EBIT Related Terms
Hua Medicine EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Hua Medicine's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hua Medicine's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hua Medicine EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hua Medicine's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hua Medicine's EV-to-EBIT falls into.
Hua Medicine's current Enterprise Value is $192.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hua Medicine's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $155.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hua Medicine (HUMDF) has a EV-to-EBIT of 1.24 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hua Medicine and its competitors. According to the industry distribution chart, Hua Medicine ranks #31 out of 692 companies in the Drug Manufacturers industry, placing it in the top 4.5%.
Is Hua Medicine's EV-to-EBIT too high?
Hua Medicine's current EV-to-EBIT is 1.24. The Drug Manufacturers industry median EV-to-EBIT is 15.60. Hua Medicine's value of 1.24 is 92.1% below this industry median. Based on the distribution chart, Hua Medicine ranks #31 out of 692 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hua Medicine has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hua Medicine's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hua Medicine ranks #31 out of 692 companies for EV-to-EBIT. This places Hua Medicine in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.60. Hua Medicine's value of 1.24 is 92.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.60, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hua Medicine's current EV-to-EBIT of 1.24 is 92.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hua Medicine and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hua Medicine's current EV-to-EBIT is 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hua Medicine stock overvalued right now?
Based on GuruFocus' analysis, Hua Medicine (HUMDF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.17, compared to a current price of $0.31 — trading 73.1% below its estimated fair value. The current EV-to-EBIT is 1.24 and 92.1% below the Drug Manufacturers industry median of 15.60. Hua Medicine's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hua Medicine (HUMDF), the current EV-to-EBIT is 1.24 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hua Medicine (HUMDF) Overvalued in 2026?
Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued.
The current stock price of $0.31 is trading 73.1% below its estimated GF Value™ of $1.17.
GuruFocus considers Hua Medicine to be Possible Value Trap.
Key valuation signals for HUMDF:
EV-to-EBIT: 1.24
GF Value™: $1.17 vs. price of $0.31 (73.1% below fair value)
Industry Position: 92.1% below the Drug Manufacturers median (#31 of 692)
No single metric tells the full story. See the HUMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
44GF Score
Get the complete analysis for HUMDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HUMDF has been successfully added to your 
